Clinical Data (NASDAQ:CLDA) announces that its major depressive disorder treatment Viibryd received approval from the FDA. The biotech company says the drug should be available in U.S. pharmacies in Q2. CLDA +67.3% premarket. (PR)
Clinical Data (NASDAQ:CLDA) announces that its major depressive disorder treatment Viibryd received approval from the FDA. The biotech company says the drug should be available in U.S. pharmacies in Q2. CLDA +67.3% premarket. (PR)